ABSTRACT
Pemphigus vulgaris is a rare immune-mediated skin disorder of the dog, usually treated with immunosuppressive medications such as oral glucocorticoids, azathioprine or ciclosporin. Herein we report the successful treatment of pemphigus vulgaris in a dog, using oclacitinib and a topical product containing fucidic acid (0.5 % w/w) and betamethasone valerate.
Le pemphigus vulgaire est une affection cutanée rare à médiation immune chez le chien, généralement traitée avec des médicaments immunosuppresseurs tels que les glucocorticoïdes oraux, l'azathioprine ou la ciclosporine. Nous décrivons ici le traitement efficace du pemphigus vulgaire chez un chien, à l'aide d'oclacitinib et d'un produit topique contenant de l'acide fucidique (0,5 % p/p) et du valérate de bétaméthasone.
O pênfigo vulgar é uma dermatopatia imunomediada dos cães, que é usualmente tratada com medicações imunossupressoras como corticoides por via oral, azatioprina ou ciclosporina. No presente estudo, relatamos o tratamento de bem sucedido de penfigp vulgaris em um cão, utilizando o oclacitinib e um produto tópico contendo ácido fusídico (0,5 % w/w) e valerato de betametasona.
El pénfigo vulgar es un trastorno inmunomediado cutáneo poco frecuente en perros, generalmente tratado con medicamentos inmunosupresores como glucocorticoides orales, azatioprina o ciclosporina. En este artículo describimos el tratamiento exitoso de pénfigo vulgar en un perro utilizando oclacitinib y un producto tópico que contiene ácido fucídico (0,5 % p/p) y valerato de betametasona.
Subject(s)
Dog Diseases , Pemphigus , Animals , Azathioprine/therapeutic use , Dog Diseases/drug therapy , Dogs , Immunosuppressive Agents/therapeutic use , Pemphigus/drug therapy , Pemphigus/veterinary , Pyrimidines/therapeutic use , Sulfonamides/therapeutic useABSTRACT
BACKGROUND: Dogs with cutaneous diseases often receive supplementation with omega-3 (n-3) and omega-6 (n-6) essential fatty acids (FA), either through their diet or the use of an oral supplement. Labelling on these products is not always clear, especially regarding the total and relative amounts of FA. OBJECTIVES: To provide clinicians with a breakdown of the FA content of selected veterinary diets, supplements and fish oil capsules so that the daily dose of supplementation can be calculated more easily. Repeated measurements of FA content over time demonstrate whether FA content changes temporally. METHODS AND MATERIALS: Eight veterinary diets, four veterinary oral FA supplements and four fish oil supplements were analysed for FA content by gas chromatography at days 0, 28 and 56. RESULTS: The n-6:n-3 ratio varied among the supplement types with the food samples having higher ratios than the liquid supplements and fish oil capsules. The composition of n-3 FA differed between products with some having higher concentrations of the less active n-3 FA alpha-linolenic acid than eicosapentaenoic acid and docosahexaenoic acid. No decreases in FA content over time were detected. CONCLUSIONS AND CLINICAL RELEVANCE: The results of this study provide the reader with a means to calculate the FA concentrations that their patient is receiving for each product tested, as well as allowing them to compare products for their differences in n-6:n-3 ratios and relative amounts of individual FA molecules. The FA concentrations did not change significantly over 56 days.
Subject(s)
Fatty Acids , Fish Oils , Animals , Capsules , Diet , Dietary Supplements , DogsABSTRACT
BACKGROUND: The aim of the study was to discover the extent of use of essential fatty acids (EFAs) in veterinary practice, conditions used in, preparation of EFA supplement used and rationale for their use and to investigate the awareness of the oxidation of some commercial fish oil supplement preparations. METHODS: A web-based questionnaire was distributed via email to a dermatology list server and posted to veterinary Facebook groups with questions relating to the use of EFAs, supplement choice, conditions used in, the level of importance of various factors regarding their use and awareness of their oxidation. RESULTS: There were 309 responses from 32 countries. EFA supplements were used by 92.2 per cent of respondents. The most commonly used preparation of EFA supplementation was veterinary oral supplements (75.1 per cent), followed by veterinary diets (14.4 per cent), shop bought fish oil supplements (7.7 per cent), enhancing the diet with oily fish (2.5 per cent) and finally using a commercial pet food (0.3 per cent). Only 46.3 per cent of respondents who used them were aware of the oxidation of EFAs. Veterinary oral supplements were perceived to be the best preserved, followed by veterinary diets and lastly commercial fish oil supplements. CONCLUSION: A large number of respondents advised the use of EFAs for veterinary dermatological conditions but less than 50 per cent were aware of the potential for EFAs to oxidise.
